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Abstract 12 
Pharmaceuticals and drugs of abuse including novel psychoactive substances (NPS) are 13 
emerging as newer contaminants in the aquatic environment. The presence of such pollutants 14 
has implications on the environment as well as public health and therefore their identification 15 
is important when monitoring water quality. This research presents a new method for the 16 
simultaneous detection of 20 drugs of abuse and pharmaceuticals in drinking water, including 17 
15 NPS, three traditional illicit drugs and two antidepressants. The developed method is based 18 
on the use of solid-phase extraction (SPE) followed by liquid chromatography-mass 19 
spectrometry (LC-MS). The SPE recoveries for the majority of target analytes ranged between 20 
62-107%. The method detection and quantification limits ranged between 0.01-1.09 ng/L and 21 
0.02-3.64 ng/L respectively. Both instrumental and method precisions resulted in relative 22 
standard deviations < 15.04%, with an accuracy of < ±8.66%. The results show that LC-MS can 23 
be an alternative to the more popular technique of liquid chromatography-tandem mass 24 
spectrometry for the analysis of drugs of abuse and pharmaceuticals in drinking water. This 25 
newly developed simultaneous detection method has been applied to drinking water collected 26 
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from the East Anglia region of the UK. Citalopram, cocaine, fluoxetine, ketamine, mephedrone, 27 
methamphetamine and methylone were detected at the range of 0.14 and 2.81 ng/L. This is 28 
the first time that the two NPS mephedrone and methylone, have been detected in UK drinking 29 
water.  30 
 31 
Keywords: drugs of abuse, novel psychoactive substances, pharmaceuticals, drinking water, 32 
solid-phase extraction, liquid chromatography-mass spectrometry.  33 
 34 
1. Introduction 35 
Drugs of abuse and pharmaceuticals are emerging contaminants identified in the aquatic 36 
environment that have received increasing public concern and scientific interest (Peng, et al., 37 
2016). These water contaminants are continuously introduced into waste water, either as 38 
parent compounds or metabolites, through human waste or improper disposal of unused or 39 
expired pharmaceuticals (Gros, et al., 2007). Previous studies have widely demonstrated that 40 
drugs of abuse and pharmaceuticals are ubiquitous in surface water and ground water, usually 41 
resulting from inefficient removal of these compounds by waste water treatment methods and 42 
the subsequent release of the resulting effluent into rivers and lakes (Cahill, et al., 2004; 43 
Kasprzyk-Hordern, et al., 2007). Aquifers are also reported to be similarly contaminated by 44 
either leakage from waste water systems or seepage from surface waters (Pal, et al., 2013).  45 
 46 
With the presence of drugs of abuse and pharmaceuticals in drinking water and the fact that 47 
these contaminants are biologically active compounds, they could have associated impacts on 48 
human health (Peng, et al., 2016). Surface and ground waters, which are collectively known as 49 
raw water, are treated by drinking water treatment plants (DWTPs) for human consumption 50 
(Pal, et al., 2013). However, as drugs of abuse and pharmaceuticals are present in raw water 51 
and current drinking water treatments are not always able to completely remove them and 52 
therefore, have been reported in drinking water at part per trillion level (ng/L) (Huerta-Fontela, 53 
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et al., 2008). Such publications are limited probably due to the analytical sensitivity needed to 54 
quantify such compounds at ultra-trace levels in drinking water samples (Peng, et al., 2016). 55 
Therefore, we describe a developed, validated and sensitive methodology for the simultaneous 56 
determination of a broad range of drugs of abuse and pharmaceuticals in drinking water. 57 
Although liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) is 58 
commonly used for the detection of drugs of abuse and pharmaceuticals in drinking water 59 
(Postigo, et al., 2008) and other methods such as capillary electrophoresis-ultraviolet detector 60 
(Castiglioni, et al., 2008) have also been reported. In this study liquid chromatography-mass 61 
spectrometry (LC-MS) is used. This is less expensive compared to LC-MS/MS and can have 62 
similar instrumental sensitivities (Díaz-Cruz, et al., 2003). Hence, LC-MS could be a cheaper 63 
method of choice and in light of this, here we report the use of LC-MS as an alternative to 64 
LC-MS/MS in the detection and quantification of drugs of abuse and pharmaceuticals in 65 
drinking water.  66 
 67 
The 15 novel psychoactive substances (NPS), 3 drugs of abuse and 2 antidepressants were 68 
chosen in this study (Table 1) due to their frequency of use in the UK and limited studies 69 
regarding their presence in drinking water [Advisory Council on the Misuse of Drugs, 2010; 70 
Baker and Kasprzyk-Hordern, 2011; Mixmag, 2012; European Monitoring Centre for Drugs and 71 
Drug Addiction (EMCDDA), 2014, 2015; Mwenesongole, et al., 2013; Health and Social Care 72 
Information Centre, 2014; United Nations Office of Drugs and Crime (UNODC), 2014].  73 
According to Home Office (2012), NPS have gained popularity among drug users, as they are 74 
easily available over the internet and can be considered as alternatives to controlled drugs. 75 
Thus, the consumption of NPS has continuously grown in the UK. However, NPS have received 76 
minimal attention in the analysis of drinking water (Peng, et al., 2016). To date, only three NPS, 77 
ketamine, mephedrone and JWH-073 have been investigated in drinking water and only the 78 
presence of ketamine has been reported in Canada at 15 ng/L (Huerta-Fontela, et al., 2008; 79 
Boleda, et al., 2011; Mendoza, et al., 2016; Rodayan, et al., 2016; Asimakopoulos, et al., 2017). 80 
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Therefore, in this study we have analysed a larger selection of NPS in drinking water belonging 81 
to cathinones, piperazines and synthetic cannabinoids, which have never been studied before.  82 
 83 
Drinking water samples were collected from the East Anglia region of the UK, which has never 84 
been investigated before with regards to the presence of drugs of abuse and pharmaceuticals.  85 
 86 
2. Material and methods 87 
2.1 Chemicals, equipment and materials 88 
The suppliers of standards and internal standards are included in Table S1 in the supplementary 89 
data. Solvents for solid-phase extraction (SPE) were of HPLC grade from Sigma-Aldrich and 90 
Fisher Scientific (UK), with the exception of ultra-pure water, which was obtained from an Elga 91 
Purelab Ultra (Veolia, UK). SPE was carried out using a Biotage (UK) PRESSURE+48, positive 92 
pressure manifold with 48 wells and Strata-X-Drug B cartridges (60 mg, 6 mL) purchased from 93 
Phenomenex (UK). A miVac DNA concentrator (Genevac, UK) was used for evaporating samples. 94 
All solvents and reagents used for the LC-MS mobile phases were of LC-MS grade from 95 
Sigma-Aldrich (UK). Nitrogen for nebulising and drying was supplied by a nitrogen generator 96 
(Parker, UK). Silanised vials, LC-MS autosampler vials and inserts were purchased from Fisher 97 
Scientific (UK) and Hichrom (UK).  98 
 99 
Preparation of stock solutions and working solutions 100 
Individual stock solutions were prepared in methanol (1 mg/mL). Internal standard stock 101 
solutions of amphetamine-d6, cocaine-d3 and fluoxetine-d6 were purchased as 0.1 mg/mL 102 
solutions in methanol or acetonitrile. All stock solutions were stored at -20°C. The internal 103 
standards were added to 1) mixed standards at the concentrations of 5, 0.1 and 0.75 ng/mL, 104 
respectively; 2) spiked waters at the concentrations of 50, 5, 25 ng/L, respectively.  105 
 106 
2.2 Drinking water collection and preparation 107 
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Raw water (before treatment) and drinking water (after treatment) grab samples were 108 
collected from three DWTPs in the East Anglia region (UK) in 2L high-density polyethylene 109 
containers and transported to the laboratory immediately after collection. A further two 110 
drinking water samples were collected from taps in Cambridge (UK). All samples were stored at 111 
5 °C and extracted within 24 h.  112 
 113 
2.3 Solid-phase extraction 114 
The SPE cartridges were conditioned with 2 mL methanol and equilibrated with 2 mL of 0.1 M 115 
hydrochloric acid. Then 200 mL of the water sample was acidified with 0.1 M hydrochloric acid 116 
(pH 2) and passed through the SPE cartridge, which was then washed with 2 mL 0.1 M 117 
hydrochloric acid followed by elution with 2 mL of 15% isopropanol/85% ethyl acetate and 2 x 118 
2 mL of 10% ammonium hydroxide/20% isopropanol/70% ethyl acetate into silanised vials. The 119 
extracts were evaporated and reconstituted with 0.1 mL LC-MS injection solvent (0.5% formic 120 
acid/5% acetonitrile/94.5% water).  121 
 122 
2.4 Liquid chromatography-mass spectrometry 123 
Analysis was carried out using a Shimadzu Ultra High Performance Liquid Chromatography 124 
Nexera system, consisting of a pump (LC-20AD), an autosampler (SIL-20A), a photo diode array 125 
detector (SPD-M20A) and a column oven (CTO-20A), equipped with a LCMS-2020 single 126 
quadrupole mass spectrometer (MS) (Shimadzu, Japan). Two analytical columns were used, a 127 
C18 column (identification and quantification) and biphenyl column (confirmation). For both 128 
columns a flow rate of 0.2 mL/min and a 10 µL injection volume were used, with the column 129 
oven and autosampler set at 30 °C and 10 °C respectively.  130 
 131 
2.4.1 Method for C18 column 132 
An Acquity UPLC BEH C18 column (2.1 x 150 mm i.d., 1.7 µm particle size) coupled to a 133 
VanGuard pre-column (2.1 x 5 mm i.d., 1.7 µm particle size) (Waters, UK) was used. Mobile 134 
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phase A was 0.5% formic acid/99.5% acetonitrile and mobile phase B was 0.5% formic acid. The 135 
gradient programme started at 10% A for 1.5 min, then ramped until 60% A after 14 min and 136 
then ramped until 100% A after 15.5 min and held for 7 min. After the run, 10% A was restored 137 
and held for 20 min to equilibrate before the next injection.  138 
 139 
2.4.2 Method for biphenyl column 140 
A Kinetex biphenyl 100 Å LC column (4.6 x 100 mm i.d., 2.6 µm particle size) was used coupled 141 
to a SecurityGuard ULTRA cartridge UHPLC biphenyl (4.6 mm i.d.) (Phenomenex, UK). Mobile 142 
phase A consisted of 0.5% formic acid/59.7% methanol/39.8% acetonitrile and mobile phase B 143 
was 0.5% formic acid. The gradient programme started at 30% A for 4 min and then ramped 144 
until 60% after 19 min and then ramped until 100% A after 20 min and held for 9 min. After the 145 
run, 30% A was restored and held for 20 min to equilibrate before the next injection.  146 
 147 
2.4.3 Mass spectrometry (MS) 148 
The MS with an electrospray ionisation (ESI) source was used in positive ionisation mode. 149 
Interface conditions were fixed as: interface temperature 350°C; desolvation line (DL) 150 
temperature 250°C; heat block temperature 200°C; nebulising gas flow 1.5 L/min; drying gas 151 
flow 15 L/min. Data acquisition was carried out in selected ion monitoring (SIM) mode. 152 
Monitored ions of studied analytes are listed in Table S2 and S3 in the supplementary data and 153 
MS analysis time was divided into ten segments and their time intervals are shown. Event time 154 
was 0.03 min. Interface voltage was 4.5 kV and detector voltage was -1.4 kV. Other MS 155 
parameters, including DL voltage and lens system voltages (qarray DC and qarray RF), were 156 
optimised for each monitored ion and their voltage values are included in both tables. Data 157 
was collected, analysed and processed using LABSolutions software. 158 
 159 
2.5 Method validation 160 
Autosampler stability, instrumental linearity, instrumental precision, method precision and 161 
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accuracy, instrumental detection and quantification limits (IDL and IQL), method detection and 162 
quantification limits (MDL and MQL) and recovery were investigated using the C18 column for 163 
quantitative purposes. In addition, IDL was studied using the biphenyl column and used for 164 
confirmation.  165 
 166 
2.6 Drinking water analysis 167 
Three raw water and five drinking water samples were extracted by SPE. For each sample, 168 
three 200 mL aliquots were used as non-spiked samples and another three 200 mL aliquots 169 
were spiked with mixed standards, resulting in the added concentrations of 5, 50 and 100 ng/L. 170 
Each non-spiked and spiked samples were extracted by SPE in triplicate (Section 2.3). A blank 171 
(ultra-pure water) and a positive control (50 ng/L mixed standard) were also analysed during 172 
the run.  173 
 174 
3 Results and discussion 175 
3.1 Separation and selectivity using liquid chromatography-mass spectrometry 176 
The use of formic acid to acidify the mobile phase not only improved the peak tailing by 177 
reducing the ionic interaction of basic analytes with the column, but was also beneficial for 178 
ionisation process (Sargent, 2013). ESI was used in positive ionisation mode, as all studied 179 
analytes showed maximum responses in this mode. The use of SIM mode, time segmentation 180 
and optimised DL and lens system voltages (Tables S2 and S3 in the supplementary data) 181 
improved selectivity and sensitivity. Figure 1 shows selected ion chromatograms of a mixed 182 
standard with internal standards using a C18 column (a) and biphenyl column (b), respectively. 183 
Based on diagnostic ions, retention times and retention indexes (the ratio of the retention time 184 
of analyte to the retention time of corresponding internal standard) shown in Table 1, the 185 
method is selective to distinguish studied analytes. Our results show that the majority of 186 
studied drugs of abuse and pharmaceuticals can be separated based on their retention times 187 
alone, including the separation of the positional isomers 3-TFMPP and 4-TFMPP. The 188 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
8 
 
protonated molecular ions [M+H]+ of the analytes were the most abundant ions and therefore 189 
monitored as diagnostic ions in SIM mode for both analytical columns, as shown in Table 1 and 190 
are also in agreement with other published literature (Baker and Kasprzyk-Hordern, 2011; 191 
Sørensen, 2011; Ammann, et al., 2012; Asimakopoulos, et al., 2017). 192 
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  Retention Time (min)  
Fig. 1 Selected ion chromatograms of a mixed standard with internal standards for LC-MS analysis using (a) a C18 column and (b) a biphenyl column 
(1) m/z 177 BZP, (2) m/z 191 MBZP, (3) m/z 164 methcathinone, (4) m/z 208 methylone, (5) m/z 193 4-MeOPP, (6) m/z 136 amphetamine, (7) m/z 142 amphetamine-d6, (8) m/z 150 
methamphetamine, (9) m/z 181 4-FPP, (10) m/z 222 butylone, (11) m/z 178 mephedrone, (12) m/z 238 ketamine, (13) m/z 197 3-CPP, (14) m/z 276 MDPV, (15) m/z 304 cocaine, (16) 
m/z 307 cocaine-d3, (17) m/z 231 3-TFMPP, (18) m/z 231 4-TFMPP, (19) m/z 325 citalopram, (20) m/z 310 fluoxetine, (21) m/z 316 fluoxetine-d6, (22) m/z 328 JWH-073, (23) m/z 376 
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Table 1 193 
Retention times (RT), retention indexes (RI), diagnostic ions and instrumental linear ranges for using a C18 and biphenyl column 194 
Analytes C18 Column Biphenyl Column C18 Column Diagnostic Ion 
d
  
(m/z) RT (min) RI RT (min) RI Linear Range (ng/mL) 
BZP 2.14 0.29 a 4.98 0.62 a 0.5-1000 177 
MBZP 2.95 0.40 a 5.39 0.67 a 0.1-1000 191 
Methcathinone 5.42 0.74 a 7.52 0.93 a 0.25-1000 164 
Methylone 6.43 0.87 a 8.91 1.11 a 0.5-1000 208 
4-MeOPP 7.26 0.99 a 9.46 1.18 a 5-1000 193 
Amphetamine-d6 7.35 – 8.05 – – 142 
Amphetamine 7.42 1.01 a 8.12 1.01 a 2.5-1000 136 
Methamphetamine 9.20 1.25 a 9.18 1.14 a 0.75-1000 150 
4-FPP 9.65 1.31 a 10.89 1.35 a 0.25-1000 181 
Butylone 10.63 1.45 a 11.60 1.44 a 0.05-500 222 
Mephedrone 11.16 0.80 b 11.36 1.41 a 0.05-1000 178 
Ketamine 11.78 0.85 b 14.99 0.75 b 0.05-500 238 
3-CPP 13.33 0.96 b 17.49 0.88 b 0.25-1000 197 
MDPV 13.78 0.99 b 20.25 1.01 b 0.1-1000 276 
Cocaine-d3  13.91 –  19.96 – – 307 
Cocaine 13.91 1.00 b 19.99 1.00 b 0.05-500 304 
3-TFMPP 14.66 1.05 b 19.14 0.96 b 0.05-1000 231 
4-TFMPP 15.00 1.08 b 20.12 1.01 b 0.05-1000 231 
Citalopram 16.31 0.90 c 26.55 0.93 c 0.025-500 325 
Fluoxetine-d6 18.11 – 28.67 – – 316 
Fluoxetine 18.15 1.00 c 28.74 1.00 c 0.5-1000 310 
JWH-073 24.01 1.33 c 33.00 1.15 c 5-1000 328 
JWH-398 25.57 1.41 c 34.76 1.21 c 5-1000 376 
a Amphetamine-d6; 
b Cocaine-d3; 
c Fluoxetine-d6; 
d Quantifier ions using both columns195 
196 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
11 
 
For the analysis of drugs of abuse and pharmaceuticals in aqueous samples, normally at least two 197 
confirmation ions are monitored along with the quantifier ion in order to improve the reliability of 198 
confirmation (Rivier, 2003). As this was not possible with the fragmentation in ESI mode, a biphenyl 199 
column with different selectivity was used for further confirmation (López de Alda and Barceló, 2000), 200 
after the studied analytes were first separated using a C18 column for quantification and initial 201 
identification. This therefore allowed our method to use a single quadrupole mass spectrometer, 202 
particularly as light fragmentation was observed for some analytes, e.g. butylone, citalopram, cocaine, 203 
cocaine-d3, ketamine and MDPV resulting in only one or two predominant ions in their mass spectra.  204 
 205 
3.2 Solid-phase extraction recoveries of drugs of abuse and pharmaceuticals 206 
To evaluate SPE recovery, three raw water samples (200 mL) were spiked with a mixed standard 207 
pre-extraction. Another set of three samples were spiked post-extraction (final concentration of 200 208 
ng/mL). Strata-X-Drug B was used providing mixed-mode cation-exchange sorbent and reverse-phase 209 
retentions. The applied SPE method (Section 2.3) was optimised based on the generic protocol of 210 
Strata-X-Drug B (Phenomenex, 2011). 0.1 M hydrochloric acid was added to convert basic groups of the 211 
target analytes to their ionised form to interact with the SPE sorbent. As the Strata-X-Drug B has acidic 212 
and non-polar groups on its sorbent surface, two elution solvents were used in tandem to elute the 213 
desired analytes from the cartridge. The 15% isopropanol/85% ethyl acetate was first used to elute two 214 
synthetic cannabinoids which are more hydrophobic and 10% ammonium hydroxide/20% isopropanol/70% 215 
ethyl acetate for the other more basic compounds. In addition, with a sample loading of 200 mL and the 216 
resulting eluant evaporated and reconstituted in 0.1 mL of solvent, this resulted in an enrichment factor 217 
of 2000 to increase the sensitivity of the method. 218 
 219 
The assessment of the SPE method and hence, its extraction recoveries (Table 2) were calculated using 220 
Eq. 1a and 1b and these are comparable to other published recoveries using similar matrices. The results 221 
also indicate good repeatability (Table 2) as shown by the relative standard deviation (RSD).  222 
% Absolute Recovery = (PA sample spiked before extraction/PA sample spiked after extraction) x 100             Eq. 1a 223 
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% Relative Recovery = (PAR sample spiked before extraction/PAR sample spiked after extraction) x 100           Eq. 1b 224 
Where, PA represents the peak area of analyte. PAR is the peak area ratio of the analyte to the internal 225 
standard. 226 
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Table 2 227 
SPE recoveries for studied drugs of abuse and pharmaceuticals using Strata-X-Drug B column 228 
Analytes 
Absolute 
Recovery 
(%, n = 3) 
RSD 
(%, n = 3) 
Relative 
Recovery 
(%, n = 3) 
RSD 
(%, n = 3) 
Reported in other academic papers 
Absolute Recovery (%) Relative Recovery (%) 
3-CPP 76 4.7 79 8.6 – – 
3-TFMPP 83 3.4 86 7.9 79 a 101 a 
4-FPP 86 2.9 81 2.8 – – 
4-MeOPP 39 14.5 39 14.9 – – 
4-TFMPP 62 8.7 65 14.1 – – 
Amphetamine 102 4.4 97 0.9 82 a; 90.5 b; 72 e; 23.2 f; 32.0 g; 33.1 h 99 a; 121.4 b; 101 c; 92 d; 92 e 
Butylone 73 6.6 67 12.9 – – 
BZP 79 5.1 72 11.2 76 a 99 a 
Citalopram 88 10.1 98 13.8 52.4 f; 50.8 g; 28.1 h 97 i 
Cocaine 96 3.1 100 0.3 89 a; 70.1 b; 86 e; 0.3 f; 0.1 g; 0.0 h 102 a; 98.5 b; 105 c; 91 d; 86 e 
Fluoxetine 94 14.7 103 2.6 53 a; 35.1 f; 40.2 g; 24.9 h; 33.13 k 101 a; 102 j; 102.44 k 
JWH-073 96 4.8 107 14.5 22.0 f; 35.6 g; 0.0 h  
JWH-398 82 14.1 99 14.9 – – 
Ketamine 87 8.3 90 13.7 90 a; 84.4 f; 66.5 g; 68.3 h 100 a; 93 d 
MBZP 72 9.7 65 14.5 – – 
MDPV 93 2.7 96 7.1 – – 
Mephedrone 45 11.1 47 14.6 14.3 f; 8.78 g; 23.0 h  
Methamphetamine 102 4.9 97 7.4 81 a; 93 e; 53.6 f; 22.2 g; 30.1 h 92 a; 108 c; 75 d; 98 e 
Methcathinone 31 12.9 30 13.3 62 a 71 a 
Methylone 72 5.4 70 12.0 – – 
a Surface water, Oasis MCX (Baker and Kasprzyk-Hordern, 2011); b Surface water, Oasis MCX (Kasprzyk-Hordern, et al., 2007); c Surface water, Oasis MCX (Zuccato, et al., 2008); d Drinking water, 229 
Oasis HLB (Boleda, et al., 2011); e Drinking water, PLRP-s (Valcárcel, et al., 2012); f Drinking water, Oasis HLB (Asimakopoulos, et al., 2017); g Drinking water, Oasis MCX (Asimakopoulos, et al., 230 
2017); h Drinking water, Supelclean ENVI-Carb (Asimakopoulos, et al., 2017); i Raw water, Oasis HLB (Gros, et al., 2012); j Drinking water, Oasis HLB (Vanderford and Snyder, 2006); k Drinking 231 
water, HySphere Resin GP (López-Serna, et al., 2010) 232 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT 
14 
 
For the absolute recoveries from raw water, as shown in Table 2, 17 out of 20 analytes had recoveries 233 
between 62-102% with < 15% RSDs, indicating good repeatability (Peters, et al., 2007). As co-extracted 234 
matrix is the common contributor to signal suppression during ESI, relative recoveries (accounting for 235 
internal standards loss) could correct for these matrix effects (Petrie, et al., 2016). In Table 2, 17 of the 236 
analytes exhibiting absolute recoveries in the range 62-102% also showed moderate and high relative 237 
recoveries (65-107%). This illustrates the applied SPE method removed undesired interferences from the 238 
water samples. When developing and validating a simultaneous detection method not all recoveries are 239 
high; however, the values were repeatable in this study and therefore precise (RSD < 15%). Although 240 
various extractions were investigated, the method reported here resulted in the highest recoveries for 241 
most of the 20 drugs of abuse and pharmaceuticals.  242 
 243 
In Table 2, 11 of the recoveries are compared with those reported in other academic papers with similar 244 
sample matrices (surface, raw and drinking waters). We were unable to compare the majority of the NPS 245 
recoveries included in this simultaneous method as these are not reported as yet. The recovery (absolute 246 
and relative) results of amphetamine, citalopram, cocaine, fluoxetine, JWH-073, ketamine, mephedrone 247 
and methamphetamine obtained in this study are close or higher to those values published previously.  248 
 249 
3.3 Method validation 250 
3.3.1 Autosampler stability 251 
Autosampler stability was evaluated at low and high concentrations of a mixed standard including 252 
internal standards (10 and 500 ng/mL) and all were stable (p > 0.05) in LC-MS injection solvent for up to 253 
five d when stored at 10°C. These were assessed using plots of PAR against injection time and the slopes 254 
of all the plots were not significantly different from zero (p > 0.05) (Saar, et al., 2010).  255 
 256 
3.3.2 Instrumental linearity 257 
Instrumental linearity (Table 1) was determined by linear regression (0.001-10000 ng/mL). The 258 
coefficients of determinations (R2) for all analytes were above 0.9992, indicating good linearity (R2 ≥ 259 
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0.9900) (UNODC, 2009). This was evaluated further using plots of relative response (mean PAR/standard 260 
concentration) against log of concentration, which resulted in all data points within ±5% of the mean 261 
relative response which fulfilled the acceptance criterion of linearity (Huber, 2007). Table 1 shows all 262 
analytes have a linear range over four to five orders of magnitude, which also covers the expected and 263 
good working range for sample analysis.  264 
 265 
3.3.3 Instrumental intra-assay and intermediate precisions 266 
Instrumental intra-assay and intermediate precisions were determined by repeating the analysis of mixed 267 
standards at low (5 ng/mL), medium (50 ng/mL) and high concentrations (500 ng/mL). Intra-assay 268 
precision results showed that the RSDs of intraday replicates (n = 6) for studied drugs of abuse and 269 
pharmaceuticals ranged from 2.51 to 15.04% at low concentration, 0.33 to 6.61% for both medium and 270 
high concentrations. These values did not exceed 15% for medium and high concentrations and 20% for 271 
low concentration, indicating good repeatability of LC-MS method (Peters, et al., 2007). Moreover, 272 
intermediate precision on three separate d resulted in RSDs of 2.60-8.70% at low concentration, 273 
1.03-6.87% at medium concentration and 0.54-3.27% at high concentration, which were all below the 20% 274 
and 15% acceptance criteria, respectively. Thus, good intermediate precision was obtained for all 275 
analytes, proving the repeatability and suitability of the simultaneous method developed in this 276 
research. 277 
 278 
3.3.4 Method precision and accuracy 279 
Quality control standards (mixed standard) at low (10 ng/L), medium (40 ng/L) and high concentrations 280 
(80 ng/L) of the target analytes were analysed in triplicate by LC-MS for calculating the method precision 281 
and accuracy. Method precision was evaluated by the RSDs of three replicates and ranged as 1.79-8.32% 282 
for low concentration, 0.67-7.57% for medium concentration and 0.63-7.15% for high concentration 283 
indicating good method precision. Method accuracy was assessed by the biases of calculated 284 
concentrations from their nominal concentrations (10, 40 and 80 ng/L). Concentrations were calculated 285 
using a calibration curve of the mean PARs against concentrations (5, 30, 50, 70 and 100 ng/L). Biases for 286 
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studied drugs of abuse and pharmaceuticals were below ±8.66% at low concentration (10 ng/L), ±7.98% 287 
at medium concentration (40 ng/L) and ±7.69% at high concentration (80 ng/L). Bias values were all 288 
within ±20% for low concentration and ±15% for medium and high concentrations, which indicates good 289 
accuracy obtained for all analytes (Peters, et al., 2007). This also proves the suitability of the 290 
simultaneous method developed using SPE and LC-MS in this research for the quantification of studied 291 
drugs of abuse and pharmaceuticals in drinking water. 292 
 293 
3.3.5 Instrumental detection and quantification limits 294 
IDL and IQL are used to specify the capabilities of the LC-MS method for detection and quantification and 295 
the results are shown in Table 3, which were calculated by root mean square error method according to 296 
Eq. 2 and 3 (Corley, 2003). Table 3 also shows comparison of IDL and IQL with other published methods. 297 
             IDL = (3/m) x [(E2/(n-2)] 1/2                     Eq. 2 298 
             IQL = (10/m) x [(E2/(n-2)] 1/2                    Eq. 3 299 
Where, m represents the slope of the linear regression fit of a plot of mean PARs of five standards 300 
against corresponding concentrations. E2 is the sum of the square of errors (difference between 301 
calculated PAR and measured PAR) for all standards. n = 5 (the number of standards). 302 
 303 
Table 3  304 
Instrumental detection and quantification limits for studied drugs of abuse and pharmaceuticals  305 
using a C18 column and biphenyl column 306 
Analytes This Study (LC-MS) Literature (LC-MS/MS) 
C18 C18 Biphenyl 
IDL (ng/mL) IQL (ng/mL) IDL (ng/mL) IDL (ng/mL) IQL (ng/mL) 
3-CPP 0.08 0.28 0.30 – – 
3-TFMPP 0.03 0.09 0.08 0.025 a 0.1 a 
4-FPP 0.09 0.28 0.06 – – 
4-MeOPP 0.85 2.84 0.08 – – 
4-TFMPP 0.03 0.09 0.08 – – 
Amphetamine 0.53 1.78 0.48 0.1 a; 0.3 b; 
0.03 c 
0.5 a; 1 b; 
0.1 c 
Butylone 0.01 0.04 0.02 – – 
BZP 0.12 0.41 0.03 0.5 a 1 a 
Citalopram 0.01 0.04 0.03 0.03 c 0.1 c 
Cocaine 0.01 0.04 0.02 0.025 a; 0.05 
b; 0.003 c 
0.1 a; 0.2 b; 
0.01 c 
Fluoxetine 0.13 0.42 0.03 0.075 a; 0.3 c 0.5 a; 1.0 c 
JWH-073 0.88 2.94 0.28 0.003 c 0.01 c 
JWH-398 0.93 3.08 0.42 – – 
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Ketamine 0.01 0.04 0.03 0.025 a; 0.15 c 0.1 a; 0.5 c 
MBZP 0.05 0.17 0.03 – – 
MDPV 0.03 0.09 0.02 – – 
Mephedrone 0.03 0.08 0.11 0.03 c 0.1 c 
Methamphetamine 0.27 0.89 0.23 0.025 a; 0.003 
c 
0.1 a; 0.01 c 
Methcathinone 0.07 0.22 0.10 0.075 a 0.5 a 
Methylone 0.13 0.42 0.01 – – 
IDL was only calculated for the biphenyl column due to it use for identification only a Baker and Kasprzyk-Hordern, 2011; b 307 
Kasprzyk-Hordern, et al., 2007; c Asimakopoulos, et al., 2017 308 
 309 
In Table 3, the IDLs of studied drugs of abuse and pharmaceuticals determined by LC-MS in this study are 310 
lower than or similar to the reported values using LC-MS/MS (Kasprzyk-Hordern, et al., 2007; Baker and 311 
Kasprzyk-Hordern, 2011; Asimakopoulos, et al., 2017). Higher IDLs and IQLs were only observed for 312 
amphetamine, JWH-073 and methamphetamine. Thus, these results show the potential of LC-MS for the 313 
analysis of drugs of abuse and pharmaceuticals at ultra-trace level in drinking water.  314 
 315 
3.3.6 Method detection and quantification limits 316 
MDL and MQL defines the limitations of whole analytical method including sample preparation and 317 
instrument analysis and are shown in Table 4, these were calculated using Eq. 4 and 5. The relative 318 
recovery results used were those presented in Table 2 and the IDLs and IQLs results are those presented 319 
in Table 3. During sample preparation (200 mL) concentrations of samples were enriched by 2000, which 320 
is into consideration in the results below.  321 
MDL = (IDL/Relative Recovery x Concentration Factor) x 100       Eq. 4 322 
MQL = (IQL/Relative Recovery x Concentration Factor) x 100       Eq. 5 323 
 324 
Table 4 325 
Method detection and quantification limits for studied drugs of abuse and pharmaceuticals  326 
using a C18 column 327 
Compound 
This Study Reported in Literature 
MDL  
(ng/L) 
MQL  
(ng/L) 
MDL 
(ng/L) 
MQL 
(ng/L) 
3-CPP 0.05 0.18 – – 
3-TFMPP 0.02 0.05 0.05 a 0.10 a 
4-FPP 0.06 0.17 – – 
4-MeOPP 1.09 3.64 – – 
4-TFMPP 0.02 0.07 – – 
Amphetamine 0.27 0.92 0.50 a; 0.2 b; 0.19 c; 2 
d; 1.33 e 
1.00 a; 1 b; 0.65 c; 4.0 e; 
1.0 j; 4.28 k 
Butylone 0.01 0.03 – – 
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BZP 0.08 0.28 1.00 a 5.00 a 
Citalopram 0.01 0.02 1.33/1.11 e; 0.24 f 4.0/3.3 e; 0.76 f; 10 l 
Cocaine 0.01 0.02 0.05 a; 0.1 b; 0.04 c; 
0.8 d; 0.13/0.11 e; 2 g 
0.10 a; 0.3 b; 0.13 c; 
0.4/0.33 e; 6 g; 0.1 j; 
0.13 k; 2.5 m 
Fluoxetine 0.06 0.20 1.00 a; 13.3 e; 0.04 
f;18 h; 20 i 
5.00 a; 40 e; 0.12 f; 66 i; 
10 l 
JWH-073 0.41 1.37 0.11 e 0.33 e 
JWH-398 0.47 1.56 – – 
Ketamine 0.01 0.02 0.08 a; 6.7/5.0 e 0.50 a; 20/16.7 e; 1.5 j 
MBZP 0.04 0.13 – – 
MDPV 0.02 0.05 – – 
Mephedrone 0.03 0.09 1.33/1.11 e 4.0/3.3 e 
Methamphetamine 0.14 0.46 0.05 a; 0.12 c; 0.6 d; 
0.13 e 
0.10 a; 0.41 c; 0.4 e; 0.5 
j; 1.28 k 
Methcathinone 0.12 0.37 0.10 a 1.00 a 
Methylone 0.09 0.30 – – 
a Baker and Kasprzyk-Hordern, 2011; b Kasprzyk-Hordern, et al., 2007; c Zuccato, et al., 2008; d Bijlsma, et al., 2009; e 328 
Asimakopoulos, et al., 2017 (used two different sample preparation protocols, see the footnote f and g of Table 2); f Paíga 329 
and Delerue-Matos, 2016; g Campestrini and Jardim, 2017; h Cahill, et al., 2004; i Gros, et al., 2006; j Boleda, et al., 2011; k 330 
Valcárcel, et al., 2012; l Alonso, et al., 2010; m López-Doval, et al., 2017 331 
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Table 4 shows that the MDLs and MQLs of the drugs of abuse and pharmaceuticals obtained in this study 332 
are comparable or in some cases lower (3-TFMPP, BZP, ketamine and methadrone as examples) than 333 
those reported previously from other studies showing again the potential of this developed simultaneous 334 
method for the detection and quantification of studied drugs of abuse and pharmaceuticals in drinking 335 
water. 336 
 337 
3.4 Analysis of drugs of abuse and pharmaceuticals in water samples 338 
The drugs of abuse and pharmaceuticals detected in the raw and drinking water samples were identified 339 
by using the validated LC-MS method. Three identification points were used as recommended by the 340 
Commission Decision 2002/657/EC (Commission Decision 2002/657/EC; Rivier, 2003): (1) one RI obtained 341 
from a C18 column, (2) one RI obtained from a biphenyl column and (3) one quantifier ion monitored in 342 
SIM mode for both the C18 and biphenyl column (Table 1). The difference of RI between the water sample 343 
and positive control for all detected analytes were within ±1% for both the C18 and biphenyl columns 344 
which fulfilled the identification criterion published by World Anti-doping Agency (2010).  345 
 346 
3.4.1 Presence of drugs of abuse and pharmaceuticals in drinking water 347 
Standard addition was used for the initial quantification of the analytes in the drinking water using this 348 
new validated LC-MS method (Frenich, et al., 2009). Of the 20 drugs of abuse and pharmaceuticals 349 
analysed for seven compounds were detected, namely citalopram, cocaine, fluoxetine, ketamine, 350 
mephedrone, methamphetamine and methylone (Table 5). These samples were drinking water samples 351 
collected from the East Anglia region of the UK. The concentrations of these analytes are shown in Table 352 
S4 in the supplementary material and were all detected in the ng/L range and above their MQL values.  353 
Their detection frequencies (number of positive samples/number of total samples) are also presented in 354 
Table S4.   355 
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Table 5 356 
Concentrations of drugs of abuse and pharmaceuticals detected in drinking water from this research 357 
(UK) and other countries 358 
Analytes Concentration range detected in 
this study (ng/L) 
Range of concentrations from 
other studies (ng/L) 
Citalopram 2.26-2.80 < 1.3-1.5 a 
Cocaine 0.19-0.84 < 0.1-85.67 b-f 
Fluoxetine 0.27 0.1-19.2 g-l 
Ketamine 0.14-1.12 15.0 c 
Mephedrone 0.77-2.81 – 
Methamphetamine 2.21 < 0.5-3.13 d, f 
Methylone 1.37 – 
a Giebułtowicz and Nałęcz-Jawecki, 2014; b Campestrini and Jardim, 2017; c Rodayan, et al., 2016; d Boleda, et al., 2011; e 359 
Mendoza, et al., 2014; f Mendoza, et al., 2016; g Wu, et al., 2015; h Paíga and Delerue-Matos, 2016; i López-Serna, et al., 360 
2010; j Benotti, et al., 2009; k Padhye, et al., 2014; l Vanderford and Snyder, 2006 361 
 362 
3.4.1.1 Traditional illicit drugs detected 363 
The presence and concentration of cocaine in drinking water analysed in this study (UK, 0.19-0.84 ng/L) 364 
is comparable to Japan (< 0.1 ng/L), European countries (0.1 ng/L), Spain (0.11-2.3 ng/L) and Latin 365 
American countries (0.6 ng/L) (Boleda, et al., 2011; Mendoza, et al., 2014; Mendoza, et al., 2016). Higher 366 
concentrations were reported in Canada (4.3 ng/L) and Brazil (< 6-22 ng/L), which could be due to low 367 
removal efficiency of clarification and post-chlorination treatment methods used (Rodayan, et al., 2016; 368 
Campestrini and Jardim, 2017), in comparison to the methods of treatment used for drinking water 369 
samples in this study, which consisted of pre-ozonation, clarification, post- ozonation, granular activation 370 
filtration and post-chlorination. An even higher cocaine concentration (85.67 ng/L) was detected in a 371 
study from Aranjuez of Spain (Mendoza, et al., 2016), which is explained as accidental/illegal disposal of 372 
cocaine at/near the sampling site, as the ratio of cocaine to its metabolite benzoylecgonine was 1.62. 373 
This is considered as an abnormal ratio (> 0.75), suggesting the measured value may not result from 374 
human consumption (Castiglioni, et al., 2008; van Nuijs, et al., 2009). 375 
 376 
The concentration of methamphetamine found in the UK from this study (2.21 ng/L) is higher than that 377 
reported in Latin American countries (< 0.5-0.6 ng/L) and Spain (< 0.5-0.6 ng/L) (Boleda, et al., 2011). A 378 
possible reason may lie in different study periods, where our study was conducted in 2016 compared to 379 
the older studies of 2008 and 2009. According to the EMCDDA (2014) report, European countries have 380 
seen an increase in the use of methamphetamine since 2012. This may explain the concentration of 381 
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methamphetamine in the UK in this study (2.21 ng/L) and correlates with the concentration of 3.13 ng/L 382 
reported in Spain from 2013 (Mendoza, et al., 2016). 383 
 384 
3.4.1.2 Antidepressants detected 385 
Both citalopram and fluoxetine were detected in drinking water in this research and their presence is not 386 
surprising as they are the most prescribed antidepressants (Health and Social Care Information Centre, 387 
2016), with the UK listed as the sixth highest consumer of antidepressants worldwide in 2013 388 
(Organisation for Economic Co-operation and Development, 2015). Citalopram was detected at the 389 
concentrations between 2.26-2.80 ng/L in this study, which is slightly higher than that found in Poland (< 390 
1.3-1.5 ng/L) (Giebułtowicz and Nałęcz-Jawecki, 2014). In addition, fluoxetine was detected at 0.27 ng/L, 391 
which is lower than 1.90-1.97 ng/L in Portugal, 2.74 ng/L in Spain, < 0.5-19.2 ng/L in the USA, but similar 392 
to 0.1-0.2 ng/L in China (Vanderford and Snyder, 2006; Benotti, et al., 2009; López-Serna, et al., 2010; 393 
Padhye, et al., 2014; Wu, et al., 2015; Paíga and Delerue-Matos, 2016) and probably due to different 394 
prescribing patterns of antidepressants across countries in the world.  395 
 396 
3.4.1.3 Novel psychoactive substances detected 397 
15 NPS were analysed in this study and three of these (ketamine, mephedrone and methylone) were 398 
detected in drinking water. The presence of NPS in drinking water is most likely related to their increased 399 
consumption in the UK. According to EMCDDA report (2015), there has been a seven-fold increase in the 400 
seizure of NPS across Europe between 2008 and 2013. 401 
 402 
Ketamine concentrations ranged between 0.14-1.12 ng/L in this research. The detection of ketamine in 403 
drinking water has also been reported in Canada at a higher concentration of 15.0 ng/L (Rodayan, et al., 404 
2016). This could be associated with the less efficient water treatment methods of clarification and 405 
post-chlorination. The treatment method used for our drinking water sample is the same as described 406 
above in section 3.4.1.1 and with a secondary amine functional group present in ketamine is a potential 407 
reaction breakdown site for ozone and chlorine treatment (Westerhoff, et al., 2005), which could explain 408 
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the low concentrations determined in our study.  409 
 410 
Mephedrone and methylone were also detected in this study at the concentrations of 0.77-2.81 and 1.37 411 
ng/L, respectively. The results are in agreement with patterns of drug consumption in the UK, where 412 
mephedrone was the most abused cathinone, followed by methylone (Mixmag, 2012). This is the first 413 
time that these two NPS have been reported to be present in drinking water, thus no data is available for 414 
comparison.  415 
 416 
4 Conclusions 417 
A novel LC-MS based method has been developed and validated for the monitoring of 20 drugs of abuse 418 
(traditional illicit drugs and NPS) and pharmaceuticals (antidepressants) from drinking water. This is the 419 
first time that 15 NPS have been investigated in drinking water. We have used SPE for sample preparation 420 
followed by LC-MS using a C18 column for detection and quantification and a biphenyl column for further 421 
confirmation. The mixed mode cation-exchange SPE cartridge (Strata-X-Drug B, 6 mL) resulted in the 422 
obtainment of high and repeatable recoveries (62-107%) for the majority of studied drugs of abuse and 423 
pharmaceuticals. Precision and accuracy for all 20 analytes were determined at three concentration 424 
levels and RSDs and biases are within the acceptance criteria of 20% RSD (Peters, et al., 2007). MDLs and 425 
MQLs (0.01-1.09 ng/L and 0.02-3.64 ng/L respectively) are also comparable to other studies using 426 
LC-MS/MS. Thus, this research shows that LC-MS can be a good alternative to popularly used LC-MS/MS 427 
in the detection and quantification of drugs of abuse and pharmaceuticals in drinking water.  428 
 429 
The method was applied for the evaluation of the presence of the 20 analytes in drinking water from the 430 
East Anglia region of the UK, which has never been reported before. Five drugs of abuse and two 431 
pharmaceuticals were detected at the range of 0.14-2.81 ng/L, including cocaine, ketamine, mephedrone, 432 
methamphetamine, methylone, citalopram and fluoxetine. Two NPS (mephedrone and methylone) have 433 
been reported for the first time in drinking water, which proves the newer emerging drugs of abuse are 434 
present in drinking water owing to their increased consumption in the UK. It is hoped that this study will 435 
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inform drinking water regulatory bodies of the presence of drugs of abuse and pharmaceuticals, as they 436 
are currently not included within the regulatory framework. In addition, this study may support future 437 
development of early monitoring strategies for such compounds in drinking water, as little is known of 438 
the possible accumulation and the health impact. In this study, drugs of abuse and pharmaceuticals were 439 
detected in drinking water at trace levels (sub ng/L), which are not sufficient to induce pharmacological 440 
and toxicological effects to humans. However, there are still concerns with the long-term exposure to 441 
these contaminants causing a chronic human health risk, as some of these compounds are lipophilic and 442 
therefore can bio-accumulate in human body. Another concern to be considered is the possible reaction 443 
with other compounds which might cause synergistic or antagonistic effects. Further information 444 
regarding human health impacts can be found in Peng, et al. (2016). 445 
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Highlights: 
• A simultaneous and sensitive LC-MS method for detecting drugs in drinking water. 
 
• Detection method for 20 drugs of abuse and pharmaceuticals including 15 NPSs. 
 
• 5 drugs of abuse and 2 antidepressants detected in samples from East Anglia, UK. 
 
• Mephedrone and methylone have been detected in drinking water for the first time. 
